James Maitland has spent his career at the cutting edge of medical technology, specializing in how robotics and the Internet of Things can bridge the gap between high-tech medical centers and remote clinics. As an advocate for global health equity, he has closely monitored how software intelligence can supplement human expertise in regions where specialist doctors are a rare resource. In this conversation, we explore the recent massive expansion of clinical decision support tools into 100 countries through a landmark partnership between OpenEvidence, Anthropic, and Penn Medicine. This initiative represents a seismic shift in public health, aiming to provide physicians in low- and middle-income regions with the same evidence-based insights available to those in the world’s most prestigious hospitals. We discuss the technical logistics of this rollout, the importance of tailoring AI to local medical guidelines, and the profound impact of having verified clinical intelligence available at the point of care in places like sub-Saharan Africa and Southeast Asia.
How do you perceive the global rollout of these specialized AI medical tools across 100 countries, and what does this mean for doctors working in regions like Uganda, Angola, or Mongolia?
The rollout across 100 countries, including places like Sudan and Haiti, is a massive step toward democratizing the highest standard of medical knowledge. For a physician in a lower-resourced setting, the primary challenge isn’t just a lack of equipment, but often a lack of immediate access to the latest medical literature and specialized expertise. By providing a specialized version of this platform for free, the partnership directly addresses the “physician capacity” crisis that has long plagued global health. It feels like we are finally moving past the era where your geography determines the quality of evidence your doctor can access. This initiative essentially puts a world-class medical library and a specialized consultant into the pocket of every healthcare provider in these regions, which is a profound shift for patient safety and treatment efficacy.
With OpenEvidence tailoring its platform to local medical guidelines, could you explain why it is vital to adapt clinical intelligence to the specific healthcare infrastructure of different regions?
You cannot simply drop a Western medical model into a different environment and expect it to work effectively; you have to account for the local healthcare infrastructure and specific regional guidelines. Daniel Nadler has been very clear that the platform is being adapted to ensure the research available is appropriate for patients in their own local contexts. This means the AI doesn’t just offer a generic answer, but one that considers what medications are actually available or what diagnostic steps are feasible in a specific country. When you build a tool from the ground up to support the particular considerations of practicing in a region, you move from a “one-size-fits-all” technology to a genuinely useful clinical partner. It’s about making sure that the summaries and evidence-based information provided are actionable within the constraints and the strengths of the local medical system.
Anthropic is providing Claude Credits and dedicated engineering support for this expansion; what does the involvement of such a high-level AI company signify for the future of public health?
Seeing a major player like Anthropic commit dedicated engineers and funding to expand access to low- and middle-income countries signals that AI’s role in public health is becoming a top priority for the tech industry. This isn’t just about donating software; it is about providing the back-end support and the computational power—the Claude Credits—necessary to run these complex systems at scale. Their involvement allows OpenEvidence to focus on the clinical side while the heavy lifting of the AI architecture is handled by the experts who built it. This collaboration applies advanced technology to one of the most pressing challenges in the world: medical attention. It demonstrates that the most sophisticated tools in our arsenal can be harnessed for the social good rather than just commercial enterprise.
OpenEvidence has reached a milestone of 1.12 million verified U.S. clinicians who consulted the system 42 million times in August alone—how does that level of trust and data influence its implementation in Africa and Asia?
That level of adoption in the U.S. provides a rigorous, real-world validation of the technology’s reliability before it even reaches clinicians in Botswana or Mongolia. When you have 1.12 million medically licensed-verified clinicians, including nurses and physician assistants, relying on a tool, it creates a massive foundation of trust. The fact that it was consulted 42 million times in a single month shows that it isn’t a novelty; it is a vital part of the daily clinical workflow. For doctors in Africa and Asia, this high volume of use serves as a guarantee that the system has been tested against a vast array of clinical questions and scenarios. It ensures that the generative AI chatbot, which simplifies and summarizes complex evidence, has been honed by the needs of millions of medical professionals.
The Botswana-UPenn Partnership has been active for 25 years; how does adding a customized AI tool change the way these long-standing academic collaborations operate on the ground?
Integrating clinical AI into a partnership that has already spent 25 years training clinicians and researching HIV/AIDS and oncology adds a powerful new layer to an established foundation. By making this technology available to the 10,000 clinicians across the Penn Medicine system and their partners in Botswana, they are creating a model for sustainable, high-tech global health. Farouk Dako noted that effective clinical AI must be shaped by local expertise, and this 25-year history provides the deep-rooted trust needed to do that successfully. Instead of replacing human researchers, the AI acts as a multiplier for the work already being done by the University of Botswana and the Ministry of Health. It allows these teams to design tools that reflect a shared conviction that local conditions must dictate how medical evidence is applied.
What is your forecast for the integration of clinical AI in global health?
I believe we are entering an era where AI will become the standard of care in every medical facility, regardless of its budget or location. Over the next few years, I expect the distinction between “local” and “global” medical evidence to disappear, as tools like OpenEvidence provide every clinician with real-time, evidence-based summaries tailored to their specific patient’s needs. We will see more sustainable partnerships where academic institutions and tech companies work in unison to ensure that no doctor is left to make a critical decision in a vacuum. Ultimately, the success of these 100-country rollouts will prove that high-level clinical intelligence is a fundamental right, not a luxury reserved for the world’s best-resourced hospitals. This transition will likely save countless lives by reducing diagnostic errors and ensuring that the most effective, locally-appropriate treatments are always at the physician’s fingertips.
